# OnCo record teclistamab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/teclistamab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "teclistamab" ;
  schema:name "Teclistamab"@en ;
  schema:description "Teclistamab was the first off-the-shelf bispecific for multiple myeloma, and is now approved after just one prior line of therapy."@en ;
  schema:url <https://onco.cc/drugs/teclistamab/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Teclistamab> ;
  owl:sameAs <http://www.wikidata.org/entity/Q113366205> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Teclistamab> ;
  onco:status "approved" ;
  onco:modality "Bispecific T-cell engager (BCMA×CD3)" ;
  schema:alternateName "Tecvayli" ;
  onco:approval "US 2022: Relapsed/refractory myeloma after ≥4 lines", "US 2026: Relapsed/refractory myeloma after ≥1 prior therapy", "EU 2022: R/R myeloma ≥3 lines (conditional, Aug 2022)" ;
  onco:acceleratedApproval "US 2022-10-25: Adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody" ;
  onco:acceleratedApprovalConfirmed "US 2026-03-05: Adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/>, <https://onco.cc/cancers/myeloma-relapsed-refractory/> ;
  onco:technologies <https://onco.cc/technologies/t-cell-engager/> ;
  onco:targets <https://onco.cc/targets/bcma/>, <https://onco.cc/targets/cd3/> ;
  onco:companies <https://onco.cc/companies/johnson-johnson/> ;
  onco:trials <https://onco.cc/trials/nct05572515/>, <https://onco.cc/trials/nct06208150/>, <https://onco.cc/trials/nct05552222/>, <https://onco.cc/trials/nct04586426/>, <https://onco.cc/trials/nct06577025/> .